Loading clinical trials...
Loading clinical trials...
A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary RLS
Conditions
Interventions
HORIZANT 300 mg
HORIZANT 600 mg
+1 more
Locations
12
United States
Stanford Sleep Medicine Center
Redwood City, California, United States
NW FL Clinical Research Group
Gulf Breeze, Florida, United States
Orlando Pediatric Pulmonary and Sleep
Winter Park, Florida, United States
PANDA Neurology/CIRCA
Atlanta, Georgia, United States
Josephson Wallack Munshower Neurology, PC
Indianapolis, Indiana, United States
Pacific Research Network
St Louis, Missouri, United States
Start Date
February 1, 2016
Primary Completion Date
October 1, 2023
Completion Date
October 1, 2023
Last Updated
June 9, 2021
NCT07179406
NCT06726785
NCT06747741
NCT07308080
NCT07194291
NCT03053427
Lead Sponsor
XenoPort, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions